Contrast Agents and Radiopharmaceuticals – Market Insights – United States

The US contrast agents and radiopharmaceutical market was severely impacted by the COVID-19 pandemic in 2020, but has already shown significant recovery in 2021 and 2022; however, it continues to be negatively impacted by disrupted supply chains, particularly due to lockdowns in Shanghai. Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities. Additionally, the shift toward value-based care will act as a barrier for certain procedures, favoring instead those that offer the highest levels of accuracy and clarity in visualization.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2032.

The COVID-19 pandemic negatively affected the contrast agent and radiopharmaceutical market.

To what extent has the COVID-19 pandemic impacted the contrast agent and radiopharmaceutical market in the US?

How has the impact of the COVID-19 pandemic varied between segments?

How quickly are procedure volumes expected to completely recover?

How has COVID-19–related use of contrast-enhanced CT and ultrasound impacted procedure volumes?

The FDA recently expanded approval for the use of CEUS in radiology procedures.

What types of procedures does this approval extend to? Which additional procedures could be approved in the future?

Which contrast agents received FDA approval?

How will competitors that do not have FDA approval react?

Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.

How are ACOs, health networks, and physicians responding to the recent findings on gadolinium retention?

What are the key differences between linear and macrocyclic GBCAs, and how will market demand for these products shift going forward?

Will other imaging modalities cannibalize contrast-enhanced MRI procedures?

Which companies (and associated products) will benefit from the shift to macrocyclic GBCAs?

The SPECT radiopharmaceuticals industry is taking precautionary measures to insulate itself from the shortening supply of Mo-99 and Tc-99.

What novel technology is showing promise that could help with global supply of Tc-99?

How will the transition from HEU to LEU reactors affect ASPs in the US market?

How will the US deal with the shortage of Mo-99?

The contrast agents segment will see a shakeup eventually due to the patent expirations and launch of generic products.

What effects will this have on competition and ASP in the contrast agents space?

How will major players secure its market share in the face of potential new competition?

Table of contents